IL7 and cancer: Thus, we are going to construct the fourth-generation CAR-T cells to secrete a PD-1- or/and CTLA-4-blocking scFv together with IL-7 and CCL19, which may maximize the efficiency of CAR-T therapy for malignant solid tumors.